title: The serum tryptase test: an emerging robust biomarker in clinical hematology.
abstract: During the past few years, a number of molecular markers have been developed in clinical hematology, most of them related to specific gene defects. However, there is also an unmet need to develop novel serologic parameters to improve diagnostics and prognostication in daily practice. Among these, the serum tryptase appears to be a most reliable biomarker of myeloid neoplasms. Elevated tryptase levels are found in subgroups of patients with mastocytosis, myelodysplastic syndrome, myeloproliferative neoplasm, acute myeloid leukemia, chronic myeloid leukemia and chronic eosinophilic leukemia. In these patients, the tryptase level is of diagnostic and/or prognostic significance. In mastocytosis, an elevated tryptase level is a minor criterion of systemic disease and in BCR-ABL1(+) chronic myeloid leukemia, elevated tryptase at diagnosis correlates with treatment responses and overall survival. In patients with elevated tryptase, the enzyme also serves as follow-up parameter and can be employed to measure treatment-responses. In the current article, we review and update the perspectives of tryptase and provide recommendations for use of this conventional biomarker in daily practice.
authors.affiliation: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Wolfgang R
authors.initials: WR
authors.lastname: Sperr
authors.forename: Karl
authors.initials: K
authors.lastname: Sotlar
authors.forename: Andreas
authors.initials: A
authors.lastname: Reiter
authors.forename: Cem
authors.initials: C
authors.lastname: Akin
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Horny
authors.forename: Michel
authors.initials: M
authors.lastname: Arock
mesh_terms: D015415:Biomarkers / Q000097:blood; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D006801:Humans; D007951:Leukemia, Myeloid / Q000175:diagnosis / Q000401:mortality; D008407:Mast Cells / Q000378:metabolism; D008415:Mastocytosis / Q000175:diagnosis; D011379:Prognosis; D017479:Receptors, Platelet-Derived Growth Factor / Q000235:genetics; D053802:Tryptases / Q000097:blood*
chemical_list: C581634:BCR-ABL1 fusion protein, human; D015415:Biomarkers; D017479:Receptors, Platelet-Derived Growth Factor; D016044:Fusion Proteins, bcr-abl; D053802:Tryptases
keywords: biomarker; mastocytosis; myeloid leukemias; prognostication; tryptase